EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Interleukin-13 Treatment of Living Lung Tissue Model Alters the Metabolome and Proteome—A Nano-DESI MS Metabolomics and Shotgun Proteomics Study

Gábor Tóth, Anastasia Golubova, Alexander Falk, Sara Bergström Lind, Mark Nicholas, Ingela Lanekoff iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25095034 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Gábor Tóth und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry-BMC, Uppsala University, 75237 Uppsala, Sweden. Hauptthemen laut MEDLINE: Interleukin-13, Lung, Proteomics, Metabolomics. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Research Council, Swedish Research Council, VINNOVA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Asthma is a chronic respiratory disease with one of the largest numbers of cases in the world; thus, constant investigation and technical development are needed to unravel the underlying biochemical mechanisms. In this study, we aimed to develop a nano-DESI MS method for the in vivo characterization of the cellular metabolome. Using air–liquid interface (ALI) cell layers, we studied the role of Interleukin-13 (IL-13) on differentiated lung epithelial cells acting as a lung tissue model. We demonstrate the feasibility of nano-DESI MS for the in vivo monitoring of basal–apical molecular transport, and the subsequent endogenous metabolic response, for the first time. Conserving the integrity of the ALI lung-cell layer enabled us to perform temporally resolved metabolomic characterization followed by “bottom-up” proteomics on the same population of cells. Metabolic remodeling was observed upon histamine and corticosteroid treatment of the IL-13-exposed lung cell monolayers, in correlation with alterations in the proteomic profile. This proof of principle study demonstrates the utility of in vivo nano-DESI MS for characterizing ALI tissue layers, and the new markers identified in our study provide a good starting point for future, larger-scale studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-13LungProteomicsMetabolomicsMetabolomeProteomeHumansMass SpectrometryEpithelial CellsAsthma

Stichwörter der Autor:innen

air–liquid interfaceamino acidasthmainterleukin-13metabolomicsmulti-omicsnano-DESIproteomics

Substanzen

Interleukin-13Proteome

Autor:innen und Institutionen

  • Department of Chemistry-BMC, Uppsala University, 75237 Uppsala, Sweden.
  • AstraZeneca R&D, 43183 Mölndal, Sweden.

ORCID-Profile: Ingela Lanekoff

Förderung

  • European Research Council
  • Swedish Research Council
  • VINNOVA
  • European Union

Zitieren

APA

Tóth, G., Golubova, A., Falk, A., Lind, S. B., Nicholas, M., & Lanekoff, I. (2024). Interleukin-13 Treatment of Living Lung Tissue Model Alters the Metabolome and Proteome—A Nano-DESI MS Metabolomics and Shotgun Proteomics Study. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25095034

Vancouver

Tóth G, Golubova A, Falk A, Lind SB, Nicholas M, Lanekoff I. Interleukin-13 Treatment of Living Lung Tissue Model Alters the Metabolome and Proteome—A Nano-DESI MS Metabolomics and Shotgun Proteomics Study. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25095034

BibTeX
@article{Tth2024,
  author = {Tóth, Gábor and Golubova, Anastasia and Falk, Alexander and Lind, Sara Bergström and Nicholas, Mark and Lanekoff, Ingela},
  title = {Interleukin-13 Treatment of Living Lung Tissue Model Alters the Metabolome and Proteome—A Nano-DESI MS Metabolomics and Shotgun Proteomics Study},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25095034}
}
Kostenlos starten →